Dysmenorrhea Pipeline Review on Effective Drugs and Therapeutic Assessment: 2017 Study

Published on : Aug 03, 2017

Albany, New York, August 3, 2017: Increase in incidence of dysmenorrhea, which is attributed to changing lifestyle, addiction to smoking and alcohol, hormonal changes and physical and mental stress, has created the need for effective treatment methods which favors the growth of this market. Several pharmaceutical companies are introducing medications and prescribed drugs for the treatment. Considering this fact, a study titled “Dysmenorrhea- Pipeline Insight, 2017” has been added to the broad archive of Market Research Hub (MRH), which provides comprehensive insights about the pipeline drugs across this Dysmenorrhea. Also, this report provides information on the therapeutic development for Dysmenorrhea, dealing with all the pipeline drugs and relative analysis at various stages covering all clinical, pre-clinical as well as discovery products.

Having menstrual cramps is one of the most common and annoying parts of the period. Pain associated with menstruation is termed as ‘dysmenorrhea’. Some women may experience cramping in or after menstrual periods in the lower abdomen as resulting of over production of certain hormones in the prostaglandins family. There are two types of dysmenorrhea, such as primary and secondary. Primary dysmenorrhea typically occurs in adolescents and usually begins 2 to 3 years following their first period. Secondary dysmenorrhea occurs mainly in women in their 30's or 40's.

The research study starts by defining the pipeline therapeutics of dysmenorrhea. It has been analyzed that the introduction of the innovative drugs and government initiatives with respect to women's health are fuelling the growth of the dysmenorrhea treatment market. On the basis of treatment, the market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), hormonal, and combined oral contraceptive. Flurbiprofen is a non-steroidal anti-inflammatory agent prescribed for pain arising from dysmenorrhea. On the other hand, CATAFLAM is a drug used for treating primary dysmenorrhea.

Further, the pipeline study contains details on dormant products and discontinued products. In addition to this, the report tracks the major market events including product launches, technological developments, mergers & acquisitions, and the innovative business strategies opted by key market players. Therapeutic assessment of all the active products by route of administration (RoA) and molecule type is also analyzed in this report. This subsequent section on pipeline products features product description, mechanism of action, Chemical details and research & development progress.

For the clear understanding of the market, the report provides data and information largely sourced from proprietary databases, primary and secondary research and in-house analysis by the team of industry experts. Some of the secondary sources utilized in the study include trade journals, news websites, search engines, magazines, industry portals and others.

Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1214092

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top